From L-R: AstraZeneca CEO Pascal Soriot, CFO Aradhana Sarin and Alexion CEO Marc Dunoyer presenting Q4 results (Reynald Castañeda for Endpoints News)
February 8, 2024 07:37 AM ESTUpdated February 9, 07:54 AM
China
Pharma

Up­dat­ed: ‘Ruth­less’ pipeline pri­or­i­ti­za­tion, obe­si­ty and Chi­na: Three take­aways from As­traZeneca’s Q4 

Ayisha Sharma

News Reporter

LON­DON — As­traZeneca on Thurs­day morn­ing teased its vi­sion on how it could po­ten­tial­ly en­ter the obe­si­ty mar­ket, as well as its views on fur­ther …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

As­traZeneca culls Phase 2 opi­oid use dis­or­der drug

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times